{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F231ac38f-41e8-4dbd-8a34-2d0cb6d39401","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/231ac38f-41e8-4dbd-8a34-2d0cb6d39401\"></iframe>","title":"Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities","description":"Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/ad97e2be-455a-4b53-ab3d-383838c145e5/cbjJP3tyd5NWFP4W5DD1CnhC.png"}